Takeda's rare disease drug's manufacturing and supply woes continue as FDA rejects supplement
Almost 3 years after Takeda had to recall a drug that can help people with the rare condition known as hypoparathyroidism, those waiting for any sign that supplies of their reliable injection from Takeda might reemerge will have to wait even longer.
Takeda announced on Tuesday that the FDA rejected its Prior Approval Supplement (PAS) submitted last August to address the formation of rubber particulates that led to the initial recall in September 2019.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
